Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: A five-year follow-up study

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Hsieh, Teng Fu ^a,b   Yang, Yu Wan ^c,d   Lee, Shang Sen ^a,b   Lin, Tien Huang ^a,b   Liu, Hsin Ho ^a,b   Tsai, Tsung Hsun ^a,b   Chen, Chi Cheng ^a,b   Huang, Yung Sung ^e   Lee, Ching Chih ^a,b  

^a Buddhist General Tzu Chi Hospital   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e Department of Otolaryngology   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID 5ALPHA REDUCTASE INHIBITOR;

AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG USE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PROSTATE HYPERTROPHY; RISK FACTOR; TAIWAN; ANALYSIS OF VARIANCE; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSTATIC HYPERPLASIA; RISK ASSESSMENT;

5-ALPHA REDUCTASE INHIBITORS; AGED; ANALYSIS OF VARIANCE; CARDIOVASCULAR DISEASES; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATIC HYPERPLASIA; RISK ASSESSMENT; TAIWAN;

EID: 84925690543     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119694     Document Type: Article

References (29)

1. Silva J, Silva CM, Cruz F. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard? Current opinion in urology. 2014; 24(1):21-8. Epub 2013/11/16. doi: 10.1097/mou. 0000000000000007 PMID: 24231531
2. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. European urology. 2013; 64(1):118-40. Epub 2013/04/02. doi: 10.1016/j.eururo.2013.03.004 PMID: 23541338
3. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. The Journal of urology. 2011; 185(5):1793-803. Epub 2011/03/23. doi: 10.1016/j.juro.2011.01.074 PMID: 21420124
4. Norman RW, Coakes KE, Wright AS, Rittmaster RS. Androgen metabolism in men receiving finasteride before prostatectomy. The Journal of urology. 1993; 150(5 Pt 2):1736-9. Epub 1993/11/01.
5. Olsson Gisleskog P, Hermann D, Hammarlund-Udenaes M, Karlsson MO. Validation of a population pharmacokinetic/pharmacodynamic model for 5 alpha-reductase inhibitors. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences. 1999; 8(4):291-9. Epub 1999/07/30.
6. Cindolo L, Pirozzi L, Fanizza C, Romero M, Sountoulides P, Roehrborn CG, et al. Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men. International urology and nephrology. 2013. Epub 2013/10/19. doi: 10.1007/s11255-013-0587-8
7. Yeap BB, Hyde Z, Almeida OP, Norman PE, Chubb SA, Jamrozik K, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. The Journal of clinical endocrinology and metabolism. 2009; 94(7):2353-9. Epub 2009/04/09. doi: 10.1210/jc.2008-2416 PMID: 19351733
8. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arteriosclerosis and thrombosis: a journal of vascular biology / American Heart Association. 1994; 14(5):701-6. Epub 1994/05/01. PMID: 8172848
9. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007; 116(23):2694-701. Epub 2007/11/28. doi: 10.1161/CIRCULATIONAHA.107.719005 PMID: 18040028
10. Jespersen CG, Norgaard M, Borre M. Androgen-deprivation Therapy in Treatment of Prostate Cancer and Risk of Myocardial Infarction and Stroke: A Nationwide Danish Population-based Cohort Study. European urology. 2013. Epub 2013/02/26. doi: 10.1016/j.eururo.2013.02.002
11. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. Journal of the National Cancer Institute. 2010; 102(1):39-46. Epub 2009/12/10. doi: 10.1093/jnci/djp404 PMID: 19996060
12. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. The Journal of urology. 2009; 181(5):1998-2006; discussion 7-8. Epub 2009/03/17. doi: 10.1016/j.juro.2009.01.047 PMID: 19286225
13. Loke YK, Ho R, Smith M, Wong O, Sandhu M, Sage W, et al. Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor-Dutasteride. Journal of clinical pharmacy and therapeutics. 2013; 38(5):405-15. Epub 2013/07/03. doi: 10.1111/jcpt.12080 PMID: 23815285
14. Kaplan SA, Holtgrewe HL, Bruskewitz R, Saltzman B, Mobley D, Narayan P, et al. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology. 2001; 57(6):1073-7. Epub 2001/05/30. PMID: 11377309
15. Souverein PC, Herings RM, Man in 't Veld AJ, de la Rosette JJ, Farmer RD, Leufkens HG. Study of the association between ischemic heart disease and use of alpha-blockers and finasteride indicated for the treatment of benign prostatic hyperplasia. European urology. 2002; 42(3):254-61. Epub 2002/09/18. PMID: 12234510
16. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. The New England journal of medicine. 2010; 362(13):1192-202. Epub 2010/04/02. 10.1056/NEJMoa0908127. doi: 10.1056/NEJMoa0908127 PMID: 20357281
17. Lee CC, Su YC, Ho HC, Hung SK, Lee MS, Chou P, et al. Risk of stroke in patients hospitalized for isolated vertigo: a four-year follow-up study. Stroke; a journal of cerebral circulation. 2011; 42(1):48-52. Epub 2010/12/04. doi: 10.1161/strokeaha.110.597070 PMID: 21127296
18. Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(12):1514-21. Epub 2013/03/20. doi: 10.1200/JCO.2012.44.6831
19. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA: the journal of the American Medical Association. 2012; 308(18):1906-14. Epub 2012/11/20. PMID: 23162861
20. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiology and drug safety. 2011; 20(3):236-42. Epub 2011/02/26. doi: 10.1002/pds.2087 PMID: 21351304
21. Chiang TL. Taiwan's 1995 health care reform. Health Policy. 1997; 39(3):225-39. Epub 1997/02/06. PMID: 10165463
22. Tseng CH. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes care. 2004; 27(7):1605-9. Epub 2004/06/29. PMID: 15220235
23. Chen YM, Lin CH, Chen HH, Chang SN, Hsieh TY, Hung WT, et al. Onset age affects mortality and renal outcome of female systemic lupus erythematosus patients: a nationwide population-based study in Taiwan. Rheumatology (Oxford). 2013. Epub 2013/10/19. doi: 10.1093/rheumatology/ket330
24. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30(6):623-30. Epub 2012/01/25. doi: 10.1200/JCO.2011.36.0917
25. Lin HC, Chao PZ, Lee HC. Sudden sensorineural hearing loss increases the risk of stroke: a 5-year follow-up study. Stroke; a journal of cerebral circulation. 2008; 39(10):2744-8. doi: 10.1161/STROKEAHA.108.519090 PMID: 18583554
26. Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 1998; 97(15):1446-52. Epub 1998/05/12. PMID: 9576424
27. D'Agostino RB, Belanger AJ, Kannel WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ. 1991; 303(6799):385-9. Epub 1991/08/17. PMID: 1912805
28. Irie K, Yamaguchi T, Minematsu K, Omae T. The J-curve phenomenon in stroke recurrence. Stroke; a journal of cerebral circulation. 1993; 24(12):1844-9. Epub 1993/12/01. PMID: 8248966
29. Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012; 379(9821):1103-11. Epub 2012/01/27. doi: 10.1016/s0140-6736(11)61619-x PMID: 22277570